cell
culturebas
product
method
may
assist
meet
increas
demand
season
influenza
vaccin
develop
product
flexibl
requir
address
influenza
pandem
cell
use
propag
cellbas
season
influenza
vaccin
optaflu
like
continu
cell
line
grow
immunocompromis
mice
produc
tumor
therefor
essenti
residu
cell
remain
within
vaccin
cell
lysat
dna
oncogen
cell
substrat
contain
oncogen
virus
oncogen
dna
multipl
redund
process
ensur
safeti
influenza
vaccin
produc
cell
probabl
residu
cell
present
dose
vaccin
approxim
residu
mdckdna
ng
per
dose
use
inactiv
influenza
viru
result
reduct
detect
dna
less
base
pair
bp
degener
pcr
specif
pcr
confirm
exclus
oncogen
virus
manufactur
process
valid
capac
remov
inactiv
virus
conclud
theoret
risk
aris
manufactur
season
influenza
vaccin
use
cell
reduc
level
effect
zero
multipl
orthogon
process
use
product
influenza
viru
infect
major
caus
respiratori
ill
import
caus
morbid
mortal
elderli
young
intercurr
diseas
vaccin
remain
princip
mean
control
season
infect
core
strategi
pandem
influenza
viru
prepared
vast
major
influenza
vaccin
produc
embryon
hen
egg
use
decadesold
technolog
one
egg
result
approxim
one
trival
vaccin
dose
egg
produc
vaccin
long
histori
safeti
issu
bioburden
use
product
system
small
proport
vaccin
allerg
reaction
egg
protein
logist
egg
product
requir
month
lead
time
vaccin
product
begin
lengthi
lead
time
result
manufactur
inflex
result
vaccin
shortag
occur
influenza
season
provid
increas
demand
season
influenza
vaccin
develop
product
flexibl
requir
address
influenza
pandem
attent
industri
govern
turn
cell
base
product
method
product
system
sever
potenti
advantag
includ
permiss
wider
rang
strain
egg
rapid
scalabl
greater
antigen
fidel
vaccin
viru
field
strain
furthermor
close
natur
cell
base
manufactur
abil
exhaust
test
cell
bank
contamin
adventiti
agent
prior
product
significantli
reduc
risk
microbi
contamin
sever
criteria
import
select
cell
line
product
inactiv
influenza
vaccin
cell
line
must
permiss
wide
rang
influenza
virus
permit
replic
high
titer
madindarbi
canin
kidney
cell
line
mdck
use
public
health
surveil
program
sensit
product
influenza
viru
detect
fulfil
requir
public
health
requir
hundr
million
dose
influenza
vaccin
facilit
use
cell
select
suspens
growth
larg
capac
fermentor
addit
select
cell
growth
anim
origin
free
aof
media
exclud
signific
potenti
sourc
introduct
virus
like
may
present
bovin
serum
manufactur
process
mdck
cell
provid
signific
advantag
vaccin
product
safeti
vaccin
deriv
cell
paramount
import
mdck
cell
deriv
late
kidney
normal
cocker
spaniel
similar
mani
continu
cell
line
mdck
cell
display
variabl
capac
produc
tumor
inject
immunocompromis
anim
tumorigen
abil
inject
cell
produc
tumor
consist
cell
type
immunocompromis
anim
oncogen
abil
cellular
element
transform
cell
inject
anim
neoplast
cell
grow
host
animalderiv
tumor
cell
use
manufactur
novarti
cellbas
season
influenza
vaccin
optaflu
tumorigen
immunocompromis
nude
mice
therefor
essenti
ensur
residu
cell
present
within
vaccin
cell
lysat
dna
oncogen
procedur
place
ensur
cell
substrat
contain
oncogen
virus
addit
step
manufactur
process
introduc
inactiv
virus
remov
inactiv
function
potenti
oncogen
dna
report
studi
conduct
multipl
redund
process
use
ensur
safeti
cellderiv
influenza
vaccin
respect
issu
tumorigen
oncogen
studi
cell
lysat
high
molecular
weight
dna
prepar
endofproduct
cell
perform
accord
ec
direct
current
intern
guidelin
test
novel
cell
substrat
studi
evalu
potenti
oncogen
cellfre
mdck
cell
compon
chromatin
host
cell
protein
etc
purifi
dna
neonat
nude
mice
rat
hamster
anim
per
sex
per
group
day
old
use
studi
treatment
subcutan
inject
ml
per
anim
evalu
includ
mortal
clinic
sign
palpat
inject
site
macroscop
examin
liver
spleen
kidney
lung
brain
lymph
node
site
inocul
microscop
evalu
select
tissu
muscl
site
inocul
lung
lesion
test
articletr
anim
one
anim
per
sex
control
group
studi
lysat
control
materi
bpl
treat
tri
buffer
test
materi
mdck
cellfre
lysat
prepar
freezethaw
lysat
bpltreat
mdck
cell
volum
cell
lysat
administ
anim
ml
neonat
rat
hamster
ml
neonat
nude
mice
due
small
size
equival
cell
respect
cell
averag
number
cell
need
produc
singl
clinic
dose
trival
vaccin
number
treat
anim
surviv
studi
termin
day
incid
tumor
summar
tabl
studi
also
perform
test
potenti
oncogen
dna
prepar
cell
influenzainfect
cell
influenzainfect
bpltreat
cell
neonat
nude
mice
rat
hamster
test
describ
control
materi
use
studi
mous
dna
concentr
dna
per
ml
dose
mg
approxim
equival
cell
averag
number
cell
need
produc
singl
clinic
dose
trival
vaccin
number
treat
anim
surviv
schedul
necropsi
day
incid
tumor
summar
tabl
mortal
neonat
mice
first
two
week
follow
dose
across
group
includ
control
death
treatmentrel
attribut
cannib
balbc
dam
provok
interfer
nest
sex
sort
dose
pup
tumor
occur
tissu
speci
studi
demonstr
destruct
intact
cell
lysi
freezethaw
cycl
bpl
treatment
abrog
tumorigen
potenti
intact
cell
dna
lysat
prepar
cell
oncogen
viabl
cell
remov
multipl
process
initi
centrifug
step
effect
remov
approxim
cell
subsequ
ultracentrifug
step
also
remov
intact
cell
might
remain
stage
manufactur
process
ultracentrifug
step
howev
valid
cell
remov
effect
result
step
includ
deriv
overal
clearanc
factor
sever
filtrat
step
manufactur
process
name
initi
filtrat
mm
filter
follow
two
filtrat
mm
filter
final
steril
filtrat
mm
filter
step
valid
effect
cell
reduct
capac
chemic
compound
use
purifi
split
inactiv
influenza
viru
investig
effect
bpl
cetyltrimethylammonium
bromid
ctab
polysorb
tween
studi
formal
document
effect
chemic
inactiv
deplet
cell
result
studi
mimic
manufactur
process
indic
worstcas
challeng
bpl
capabl
reduc
number
viabl
cell
least
cation
deterg
ctab
strongest
effect
cell
complet
destruct
cell
cultur
within
min
extent
deplet
live
cell
ctab
shown
log
howev
toxic
effect
reagent
cell
viabil
process
would
like
much
higher
observ
experiment
approach
sinc
retent
period
cell
reagent
would
much
longer
process
experiment
approach
consid
point
view
reduct
capac
chemic
moieti
unquestion
underestim
much
higher
deplet
rate
anticip
taken
togeth
chemic
solut
use
process
vaccin
capabl
decreas
number
viabl
cell
log
chromatographi
step
use
manufactur
viral
vaccin
also
like
effect
cell
remov
howev
ultracentrifug
step
chromatograph
step
specif
valid
cell
remov
therefor
count
overal
viral
clearanc
factor
cumul
cell
remov
potenti
manufactur
process
e
centrifug
filtrat
chemic
treatment
e
combin
effect
greater
log
reduct
cell
number
assum
approxim
million
cell
need
produc
dose
vaccin
intact
cell
remov
manufactur
process
point
less
one
cell
dose
vaccin
practic
purpos
probabl
intact
cell
influenza
vaccin
zero
specifi
dna
content
final
trival
bulk
doseadjust
final
drug
product
less
ngvaccin
dose
valu
consist
guidelin
fda
draft
guidanc
dna
content
vaccin
produc
continu
cell
line
fda
draft
guidanc
howev
note
vaccin
produc
continu
cell
line
tumorigen
addit
consider
may
appli
requir
degrad
dna
certain
size
manufactur
optaflu
sever
step
elimin
dna
step
includ
cellulos
sulfat
ionexchang
chromatographi
bind
influenza
viru
allow
dna
pass
subsequ
ctab
precipit
step
inter
alia
precipit
dna
dna
content
vaccin
monitor
throughout
product
process
total
dna
assay
system
md
analyt
technolog
ca
averag
residu
dna
content
manufactur
run
differ
vaccin
strain
ng
per
dose
optaflu
manufactur
viral
harvest
inactiv
bpl
bpl
alkyl
agent
react
inter
alia
dna
primarili
guanin
residu
bpl
also
reduc
dna
size
induc
strand
break
crosslink
dna
dna
chain
protein
addit
reduc
size
dna
bpl
markedli
reduc
abil
serv
templat
dna
polymeras
note
later
author
specif
condit
bpl
treatment
abolish
trace
dna
activ
evalu
polymeras
chain
reaction
pcr
dna
greater
base
pair
bp
length
detect
final
monoval
vaccin
bulk
capillari
gel
electrophoresi
cge
undoubtedli
dna
greater
ca
bp
amount
level
detect
cge
method
may
dna
approach
bp
length
suffici
potenti
encod
oncogen
protein
therefor
mathemat
statist
model
approach
use
estim
potenti
amount
long
dna
sequenc
use
approach
distribut
dna
length
bpl
treatment
estim
rel
number
break
induc
bpl
treatment
distribut
dna
length
follow
bpl
treatment
evalu
mathemat
model
similar
bose
git
result
evalu
provid
estim
rel
amount
dna
greater
chosen
length
eg
bp
bp
level
detect
cge
methodolog
model
indic
three
product
run
evalu
residu
dna
bp
length
amount
dna
bp
approach
zero
detect
oncogen
dna
virus
two
stage
process
implement
fig
stage
treatment
cell
sodium
butyr
tpa
day
induc
viral
dna
amplif
lytic
replic
stage
examin
cell
pellet
transmiss
electron
microscopi
pcr
adenovirus
canin
papillomavirus
furthermor
detect
presenc
unknown
herpesvirus
polyomavirus
degener
pcr
capabl
detect
wide
rang
herpesvirus
polyomavirus
undertaken
day
test
articl
cell
seed
densiti
cellsml
cm
flask
ml
cultur
medium
cellsflask
day
cell
form
monolay
cultur
medium
replac
fresh
medium
contain
mm
sodium
butyr
plu
ngml
tpa
bottl
fresh
medium
alon
act
control
induct
step
bottl
level
induc
agent
determin
follow
preliminari
cytotox
experi
cell
line
level
shown
induc
maximum
induct
cell
induc
uninduc
test
articl
cell
cell
monitor
throughout
induct
period
viabil
neg
control
mdck
cell
deriv
directli
atcc
stock
atcc
seed
treat
like
untreat
test
articl
cell
supernat
materi
cell
pellet
prepar
day
day
sampl
total
dna
pellet
cell
extract
use
qiagen
dna
extract
kit
cell
harbor
latent
use
posit
control
induct
step
cell
seed
day
cm
cultur
flask
ml
medium
cell
flask
presenc
absenc
induc
agent
preliminari
studi
shown
peak
induct
occur
day
treatment
induct
measur
analysi
cell
specif
valid
realtim
pcr
genom
copi
number
normal
copi
number
cellular
bactin
gene
exclud
presenc
canin
papillomavirus
specif
valid
realtim
pcr
conduct
cell
pellet
induc
uninduc
cell
test
articl
control
sampl
test
triplic
intern
posit
control
consist
sampl
neg
nucleic
acid
spike
posit
sampl
detect
limit
assay
exogen
intern
posit
control
includ
pcr
master
mix
establish
neg
reaction
truli
neg
due
fail
amplif
neg
control
consist
appropri
pcr
mix
neg
control
human
placent
dna
ad
sentinel
extract
control
design
detect
airborn
pcr
contamin
consist
extract
kit
reagent
process
alongsid
test
articl
valid
assay
triplic
neg
control
requir
neg
posit
control
includ
intern
posit
control
demonstr
amplif
target
sequenc
specif
pcr
canin
adenoviru
conduct
mcb
found
neg
induct
experi
interest
exclud
presenc
heterolog
potenti
transform
adenovirus
convent
pcr
use
primer
target
capsid
hexon
gene
employ
induc
uninduc
cell
pcr
detect
human
adenovirus
addit
broader
specif
nonhuman
adenovirus
degener
pcr
assay
herpesvirus
polyomavirus
conduct
previous
describ
cell
duplic
bottl
induc
uninduc
cell
control
mdck
e
atcc
cell
dna
sampl
quantifi
use
nanodrop
spectrophotomet
labtech
uk
mg
dna
use
per
reaction
sampl
analyz
herpesviru
genom
use
primer
deriv
viral
polymeras
gene
sequenc
two
outer
pcr
perform
ml
reaction
product
assay
amplifi
two
seminest
pcr
shown
fig
reaction
includ
control
test
dna
templat
pcr
primer
mm
hotstart
taq
mastermix
kit
qiagen
total
volum
ml
thermal
cycl
perform
genamp
pcr
system
appli
biosystem
use
follow
cycl
paramet
c
min
follow
cycl
c
c
min
c
min
follow
cycl
anneal
temperatur
c
final
extens
c
min
reaction
product
outer
seminest
reaction
purifi
use
pcr
purif
kit
vh
bio
ltd
uk
purifi
pcr
product
subject
capillari
electrophoresi
abi
prism
genet
analyz
evalu
use
genescan
softwar
appli
biosystem
three
posit
control
sampl
hcmv
pol
plasmid
pol
plasmid
ebv
posit
raji
cell
dna
use
spike
level
copi
templat
neg
control
consist
water
includ
everi
two
sampl
final
sampl
mdck
e
atcc
use
control
nonspecif
amplif
product
degener
pcr
polyomavirus
conduct
similarli
use
primer
deriv
sequenc
larg
antigen
shown
fig
posit
control
plasmid
contain
tantigen
sequenc
jcv
bpyv
use
copi
neg
control
describ
degener
herpesviru
assay
analysi
induc
cell
indic
increas
sequenc
induc
cell
compar
uninduc
cell
normal
amount
bactin
dna
sampl
examin
cell
profil
duplic
treatment
uninduc
induc
cell
indic
presenc
herpesviru
virion
tpa
plu
sodium
butyr
treat
cell
wherea
virion
detect
untreat
cell
duplic
sampl
induc
uninduc
cell
pcr
reaction
control
met
appropri
valid
criteria
real
time
ccr
canin
oral
papillomaviru
canin
papillomavirus
neg
limit
detect
lod
copi
per
reaction
equival
copi
cell
similarli
convent
pcr
adenovirus
neg
lod
degener
pcr
herpesvirus
posit
control
clearli
posit
seminest
analysi
copi
per
reaction
addit
ebv
sequenc
detect
primer
set
sequenc
detect
primer
set
emphas
mismatch
primer
sequenc
toler
within
conserv
region
viral
genom
induc
uninduc
test
articl
cell
control
mdck
cell
give
rise
amplifi
fragment
expect
size
rang
herpesviru
product
polyomaviru
degener
pcr
posit
control
expect
specif
control
gave
posit
result
copi
level
amplifi
product
expect
size
polyomaviru
detect
induc
uninduc
test
articl
cell
control
mdck
cell
vertebr
cell
contain
defect
nondefect
retrovir
sequenc
may
express
mrna
cell
speci
virion
spontan
produc
may
induc
treatment
agent
includ
mutagen
like
deoxyuridin
idu
azac
inhibitor
dna
methyltransferas
capac
cell
produc
retrovirus
evalu
combin
treatment
agent
follow
detect
virus
use
transmiss
electron
microscopi
tem
highli
sensit
fpert
assay
revers
transcriptas
addit
induc
cell
cocultiv
cell
permiss
wide
rang
retrovirus
amplifi
potenti
low
level
viru
duplic
cm
flask
seed
test
articl
cell
day
day
one
medium
replac
fresh
medium
contain
mgml
azac
mgml
idu
similar
cultur
establish
without
induc
agent
evalu
toxic
induc
drug
duplic
cultur
human
hek
cell
atcc
infect
felin
leukemia
viru
use
posit
control
duplic
cultur
murin
kbalb
cell
atcc
act
posit
control
induct
retroviru
express
day
two
h
treatment
induc
agent
medium
remov
test
control
cultur
cell
refe
medium
without
induc
agent
day
day
remov
induc
agent
supernat
harvest
analysi
pert
fresh
medium
ad
pert
assay
conduc
previous
describ
use
realtim
pcr
detect
cdna
revers
transcrib
plant
viru
target
day
cell
induc
uninduc
test
articl
cell
prepar
tem
fixat
glutaraldehyd
paraformaldehyd
cacodyl
buffer
cell
postfix
osmium
tetroxid
h
stain
en
bloc
uranyl
acet
rins
dehydr
ethanol
seri
embed
araldit
day
three
cell
remov
induc
test
articl
cell
cocultiv
presenc
mgml
polybren
human
hek
cell
control
mdck
cell
atcc
cocultiv
maintain
day
cell
passag
least
week
test
articl
cell
also
passag
without
indic
cell
test
residu
revers
transcriptas
activ
control
indic
cell
grown
passag
without
test
articl
cell
evalu
background
revers
transcriptas
activ
posit
control
hek
cell
infect
infecti
unit
felin
leukemia
viru
felv
cultur
passag
way
test
articl
cocultur
least
median
profil
ie
nuclear
profil
visibl
induc
uninduc
mdck
cell
examin
observ
membran
bud
virion
cytoplasm
intracellular
virion
undertaken
retrovirus
adventiti
agent
detect
order
quantit
assess
potenti
risk
repres
adventiti
virus
data
collect
growth
properti
variou
relev
virus
cell
viru
inactiv
viru
clearanc
vaccin
manufactur
process
detect
limit
appli
pcr
method
detect
adventiti
virus
viru
growth
studi
inocul
repres
virus
suspens
cell
follow
extend
cultiv
product
medium
dna
virus
studi
parvoviru
minut
viru
mice
circoviru
porcin
circoviru
polyomavirus
bk
viru
avian
polyomaviru
herpesvirus
herp
simplex
viru
human
cytomegaloviru
epsteinebarr
viru
adenovirus
human
adenovirus
type
rna
virus
studi
reovirus
mammalian
reoviru
two
avian
reoviru
strain
enterovirus
echoviru
coxsacki
b
viru
rhinovirus
rhinoviru
coronaviru
paramyxovirus
parainfluenza
two
human
metapneumovirus
two
human
respiratori
syncyti
virus
rou
sarcoma
viru
avian
birnaviru
least
infecti
unit
viru
inocul
ml
suspens
cultur
cellsml
cultur
kept
spinner
flask
incub
c
day
sampl
cell
medium
taken
directli
inocul
interv
thereaft
day
monitor
growth
inocul
agent
sampl
cultur
volum
cell
remov
volum
replac
fresh
medium
maintain
grow
cultur
cultur
sampl
includ
cell
frozen
without
separ
remov
cell
end
studi
sampl
includ
inoculum
viru
sampl
titer
togeth
day
essenti
virus
agent
use
growth
studi
also
use
assess
capac
bpl
inactiv
process
inactiv
studi
maximum
impur
present
ie
unpurifi
harvest
appli
bpl
incub
inactiv
shortest
specifi
inactiv
time
period
standard
micro
titer
plate
viru
titrat
use
measur
start
tire
end
titer
inactiv
end
titer
expect
significantli
detect
limit
microtitr
log
larger
volum
ml
undilut
sampl
inocul
cultur
flask
test
residu
viru
lower
detect
limit
start
end
titer
compar
use
calcul
log
reduct
viru
select
model
virus
use
studi
viru
inactiv
remov
select
purif
process
step
infecti
viru
spike
process
materi
process
step
pass
respect
purif
procedur
small
scale
sampl
process
step
titer
comparison
spike
start
materi
necessari
cytotox
sampl
dilut
test
residu
viru
detect
limit
standard
microtitr
test
assay
plate
larger
volum
two
envelop
virus
herp
simplex
viru
murin
leukemia
viru
three
nonenvelop
virus
simian
viru
porcin
parvoviru
use
viru
remov
studi
studi
condit
reflect
worstcas
condit
lowest
expect
deterg
concentr
use
detach
surfac
antigen
shortest
process
time
separ
step
valid
studi
altogeth
studi
model
virus
conduct
collabor
analysi
gmbh
part
newlab
bioqual
ag
erkrath
germani
combin
data
viru
growth
cell
inactiv
process
remov
variou
model
virus
consider
applic
detect
limit
viru
exclus
test
processspecif
risk
assess
made
use
quantit
data
rel
infecti
dose
methodolog
quantit
risk
assess
describ
elsewher
note
viru
remov
studi
robust
studi
done
public
thu
result
present
partli
vari
publish
earlier
tabl
realist
worstcas
assumpt
made
adequ
cover
variabl
potenti
contamin
viru
titer
viru
passag
number
dilut
inactiv
result
differ
type
viru
famili
start
coisol
contamin
isol
influenza
viru
strain
human
throat
sampl
plu
contamin
avian
virus
assum
occur
eggpassag
viru
titer
estim
subsequ
step
vaccin
strain
select
passag
work
seed
vaccin
manufactur
level
contamin
aerosol
droplet
infect
human
oper
assum
human
virus
calcul
continu
entir
manufactur
process
includ
ferment
purif
formul
final
trival
vaccin
consid
also
result
obtain
worstcas
robust
studi
end
result
risk
assess
term
human
infecti
dose
per
vaccin
dose
avian
polyomaviru
respiratori
syncyti
viru
accord
end
result
influenza
viru
would
tabl
multipl
independ
test
process
implement
gmp
ensur
safeti
optaflu
regard
tumorigen
oncogen
risk
theoret
risk
associ
tumorigen
relat
possibl
inocul
viabl
cell
recipi
vaccin
follow
growth
cell
recipi
risk
occurr
practic
purpos
zero
cell
partli
kill
replic
influenza
viru
multipl
specif
step
manufactur
process
remov
inactiv
remain
cell
process
includ
centrifug
filtrat
chemic
inactiv
membran
disrupt
viral
split
filtrat
step
bpl
viru
inactiv
stage
viral
split
activ
specif
investig
determin
abil
remov
inactiv
cell
oper
orthogon
mechan
collect
evalu
step
capac
reduc
cellular
concentr
log
valid
data
log
given
approxim
million
cell
requir
produc
one
dose
vaccin
risk
cell
one
vial
less
continu
cell
line
e
inde
cell
substrat
e
possibl
latent
oncogen
viru
might
present
need
detail
consider
case
dna
virus
certain
member
herpesviru
polyomaviru
papillomaviru
famili
induc
tumor
host
speci
adenovirus
shown
oncogen
heterolog
host
virus
famili
may
also
establish
latent
infect
becom
integr
chromosom
dna
follow
abort
replic
addit
virus
might
introduc
cell
viru
seed
human
contamin
via
raw
materi
viral
risk
counter
two
independ
approach
first
rigor
analysi
cell
undertaken
exclud
presenc
infecti
oncogen
virus
infecti
oncogen
viral
genom
secondli
manufactur
process
shown
capabl
inactiv
potenti
viru
contamin
high
level
neonat
anim
highli
suscept
presenc
oncogen
virus
tumor
induc
neonat
nude
mice
rat
hamster
cell
lysat
high
molecular
weight
dna
extract
cell
therefor
neither
infecti
virion
infecti
genom
capabl
induc
tumor
present
definit
analysi
presenc
oncogen
dna
virus
provid
degener
pcr
capabl
broad
detect
herpesvirus
polyomavirus
method
shown
capabl
detect
new
virus
emphas
util
role
possibl
detect
oncogen
herpesvirus
enhanc
induct
procedur
result
genom
amplif
recrudesc
latenc
none
assay
involv
degener
pcr
herpesvirus
polyomavirus
broad
pcr
adenovirus
specif
pcr
papillomavirus
reveal
presenc
oncogen
dna
viru
sequenc
dog
known
infect
exogen
retroviru
known
possess
provirus
encod
infect
endogen
retroviru
although
claim
canin
retrovirus
made
time
time
none
independ
confirm
speci
infecti
endogen
retrovirus
may
express
induct
mutagen
inhibitor
dna
methyltransferas
sinc
experi
conduct
khan
colleagu
formul
specif
algorithm
approach
exclus
retrovirus
vaccin
cell
substrat
studi
conduct
accord
approach
pert
assay
retrovirus
highli
sensit
method
detect
famili
virus
reli
specif
genom
inform
retroviru
product
detect
follow
induct
cocultur
cell
known
permiss
rang
retrovirus
growth
studi
well
systemat
literatur
studi
shown
mdck
cell
support
growth
limit
spectrum
virus
herp
simplex
viru
parainfluenza
viru
reoviru
almost
ident
virus
grow
embryon
egg
contrast
egg
howev
mdck
cell
support
growth
avian
virus
compar
exist
eggderiv
vaccin
mdck
cell
use
produc
vaccin
viru
influenza
viru
strain
isol
egg
introduc
new
higher
virusassoci
risk
host
spectrum
mdck
cell
similar
embryon
egg
use
simpl
risk
score
algorithm
estim
compar
risk
adventiti
agent
differ
cell
substrat
use
viru
isol
vaccin
manufactur
mdck
cell
use
produc
vaccin
eggderiv
isol
gave
either
lower
risk
score
embryon
egg
use
isol
product
modern
viru
product
method
describ
common
recombin
protein
monoclon
antibodi
product
tradit
vaccin
manufactur
downstream
manufactur
step
capac
remov
inactiv
virus
particularli
action
bpl
processspecif
quantit
risk
assess
made
wide
rang
potenti
process
contamin
includ
latent
oncogen
virus
polyomavirus
adenovirus
retrovirus
herpesvirus
parvovirus
model
calcul
show
even
worstcas
condit
unlik
case
contamin
process
abl
reduc
contamin
level
millionfold
infecti
level
even
calcul
worst
case
contamin
level
consid
final
vaccin
product
would
still
unabl
transmit
infecti
virus
although
sever
theoret
way
exogen
dna
could
contribut
oncogenesi
includ
insert
inactiv
tumor
suppressor
gene
transcript
regulatori
microrna
princip
risk
relat
domin
oncogen
oncogen
result
transform
would
present
fulllength
copi
transfect
recipi
cell
becom
integr
chromosom
region
favor
express
burn
report
dna
could
directli
oncogen
experi
use
high
level
plasmid
contain
activ
hra
gene
recent
scientist
fda
made
import
contribut
demonstr
quantit
limit
direct
dna
oncogen
initi
studi
mg
plasmid
capabl
express
ra
myc
requir
induc
tumor
mice
recent
lower
oncogen
level
dual
oncogen
plasmid
ng
recent
data
reduc
safeti
margin
estim
ng
high
molecular
weight
dna
method
reduc
size
function
activ
dna
like
bpl
treatment
increas
safeti
factor
ie
invers
risk
conclus
safeti
margin
base
intact
high
molecular
weight
dna
treatment
bpl
radic
reduc
function
size
dna
note
even
sequenc
bp
present
rel
encompass
correct
sequenc
encod
oncogen
methodolog
enabl
us
differenti
fragment
still
intact
structur
bplcrosslink
otherwis
impair
dna
fragment
howev
residu
dna
approach
size
maximum
amount
ng
per
dose
dna
present
optaflu
less
calcul
bp
ie
less
pg
even
lower
percentag
bp
use
cell
base
vaccin
potenti
transform
strategi
prophylaxi
season
pandem
influenza
demonstr
safeti
vaccin
essenti
prerequisit
conclud
multipl
orthogon
process
use
product
theoret
risk
aris
manufactur
optaflu
use
cell
reduc
level
effect
zero
